NANOG and lung cancer: Nanog overexpression was significantly correlated with poor OS (publication year 2010-2016 subgroup: HR = 1.56, 95% CI = 1.33-1.83, P  ≤ 0.001 and publication year 2017 subgroup: HR =2.94, 95% CI = 2.22-3.88, P ≤ 0.001; Table 3) and poor DFS (publication year 2010-2016 subgroup: HR = 1.34, 95% CI = 1.08-1.67, P = 0.008 and publication year 2017 subgroup: HR = 2.92, 95% CI = 2.00-4.26, P ≤ 0.001; Table 4) in lung cancer.